- Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Statin; Drug: Ace Inhibitor; Drug: Placebo; Drug: Combination therapy
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Juvenile Diabetes Research Foundation; Diabetes UK; British Heart Foundation; Pfizer; The University of Western Australia; The Hospital for Sick Children; University of Oxford; St Thomas' Hospital, London
Recruiting - verified April 2012 - Condition: Systemic Lupus Erythematosus
Intervention: Drug: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified March 2012 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: Adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: University of Glasgow; University of Glasgow; NHS Greater Glasgow and Clyde; Juvenile Diabetes Research Foundation; Imperial College London; University of Wisconsin School of Medicine and Public Health; University of Dundee; Merck Serono S.A., Geneva; Itamar-Medical, Israel; University of Western Ontario, Canada; University of Melbourne; Steno Diabetes Center; Maastricht University Medical Center
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Optimus Clinical Research; Optimus Clinical Research; Arthritis Australia, Abbott Australia
Recruiting - verified November 2011 - Condition: Multiple Sclerosis
Intervention: Drug: Fampridine
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Juvenile Idiopahtic Arthritis
Intervention: Drug: etanercept
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Cutaneous Lupus; Lupus
Interventions: Drug: AMG 557; Drug: AMG 557 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Type 1 Diabetes Mellitus; Retinopathy; Diabetic Nephropathy
Interventions: Drug: Fenofibrate; Drug: Inert lactose placebo
Sponsors: University of Sydney; University of Sydney; Abbott; University of Melbourne; St Vincents Hospital, Melbourne; Melbourne Health; Royal Prince Alfred Hospital, Sydney, Australia
Not yet recruiting - verified March 2011 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Epratuzumab; Drug: Epratuzumab; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Multiple Sclerosis Relapse
Interventions: Drug: Teriflunomide (HMR1726); Drug: Matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Fostamatinib; Drug: Fostamatinib; Drug: Fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: LY2127399
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 4 weeks; Drug: Placebo every 2 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 4 weeks; Drug: Placebo every 2 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: fostamatinib; Drug: fostamatinib; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Methotrexate; Drug: Abatacept Placebo; Drug: Methotrexate Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Rebif)
Sponsors: Merck KGaA; Merck KGaA
Recruiting - verified August 2011 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-293987; Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified April 2012 - Condition: Crohn Disease
Intervention: Drug: Mesenchymal stromal cells (MSC) for infusion
Sponsors: Royal Perth Hospital; R.P.Herrmann; The Queen Elizabeth Hospital; Concord Hospital; Sir Charles Gairdner Hospital
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: SAR153191 (REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Recruiting - verified January 2012 - Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon β 1a; Drug: DAC HYP
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified March 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2012 - Condition: Myasthenia Gravis
Interventions: Procedure: thymectomy; Drug: prednisone
Sponsors: University of Alabama at Birmingham; Gary Cutter, PhD; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified October 2011 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012
 |
Join Clinical Trials for Autoimmune Diseases - Australia |
